Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Wen-Jing Ning, Xue Liu, Hong-Ye Zeng, Zhi-Qiang an, Wen-Xin Luo & Ning-Shao Xia. (2022) Recent progress in antibody-based therapeutics for triple-negative breast cancer. Expert Opinion on Drug Delivery 19:7, pages 815-832.
Read now
Read now
Jasmeet Kaur, Paramveer Singh, Thomas Enzler & Vaibhav Sahai. (2021) Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Expert Opinion on Emerging Drugs 26:2, pages 103-129.
Read now
Read now
Astero Klampatsa, Vivian Dimou & Steven M. Albelda. (2021) Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opinion on Biological Therapy 21:4, pages 473-486.
Read now
Read now
Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Valéry Moine, Laurence Chatel, Lucile Broyer, Guillemette Pontini, Tereza Bautzova, Flora Juan, Sebastien Calloud, Nicolas Bosson, Maud Charreton, Krzysztof Masternak, Vanessa Buatois & Limin Shang. (2020) Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. mAbs 12:1.
Read now
Read now
Linda Ye, Shaokang Ma, Bruce W. Robinson & Jenette Creaney. (2019) Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. Expert Review of Respiratory Medicine 13:2, pages 181-192.
Read now
Read now
Articles from other publishers (21)
Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann & Fabian Dominik Mairinger. (2023) One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy. International Journal of Molecular Sciences 24:7, pages 6356.
Crossref
Crossref
Seyedeh Zahra Bahojb Mahdavi, Fatemeh Oroojalian, Shirin Eyvazi, Maryam Hejazi, Behzad Baradaran, Nasser Pouladi, Mohammad Reza Tohidkia, Ahad Mokhtarzadeh & Serge Muyldermans. (2022) An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. International Journal of Biological Macromolecules 208, pages 421-442.
Crossref
Crossref
Davinder Singh, Divya Dheer, Abhilash Samykutty & Ravi Shankar. (2021) Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. Journal of Controlled Release 340, pages 1-34.
Crossref
Crossref
Quy Le, Sommer Castro, Thao Tang, Anisha M. Loeb, Tiffany Hylkema, Cyd Nourigat McKay, LaKeisha Perkins, Shivani Srivastava, Lindsey Call, Jenny Smith, Amanda Leonti, Rhonda Ries, Laura Pardo, Michael R. Loken, Colin Correnti, Salvatore Fiorenza, Cameron J. Turtle, Stanley Riddell, Katherine Tarlock & Soheil Meshinchi. (2021) Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical Cancer Research 27:20, pages 5718-5730.
Crossref
Crossref
Hung-Ju Hsu, Chao-Ping Tung, Chung-Ming Yu, Chi-Yung Chen, Hong-Sen Chen, Yu-Chuan Huang, Pei-Hsun Tsai, Su-I Lin, Hung-Pin Peng, Yi-Kai Chiu, Yueh-Liang Tsou, Wei-Ying Kuo, Jhih-Wei Jian, Fei-Hung Hung, Chiao-Yun Hsieh, Michael Hsiao, Simon Shih-Hsien Chuang, Chia-Ning Shen, Yong Alison Wang & An-Suei Yang. (2021) Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries. Scientific Reports 11:1.
Crossref
Crossref
Qiyu Li, Wenjing Li, Keyuan Xu, Yutong Xing, Yu Ding, Zhe Jing, Xi Wang & Zhangyong Hong. (2021) Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand. International Journal of Pharmaceutics 602, pages 120647.
Crossref
Crossref
Jyoti RoyElaine M. JagodaFalguni BasuliOlga VasalatiyTim E. PhelpsKaren WongAnita T. TonUrs B. HagemannAlan S. CuthbertsonPatricia E. ColeRaffit HassanPeter L. ChoykeFrank I. Lin. (2021)
In Vitro
and
In Vivo
Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
. Cancer Biotherapy and Radiopharmaceuticals 36:4, pages 316-325.
Crossref
Crossref
Mary Ellen Molloy, Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, Vaishnavi Ganti, Adrie Jones, Susan D. Jones, Kathryn L. Strobel, Purbasa Patnaik, Kenneth Sexton, Laurie Tatalick, Timothy Z. Yu, Patrick A. Baeuerle, Che-Leung Law & Holger Wesche. (2021) Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. Clinical Cancer Research 27:5, pages 1452-1462.
Crossref
Crossref
Guendalina Froechlich, Chiara Gentile, Luigia Infante, Carmen Caiazza, Pasqualina Pagano, Sarah Scatigna, Gabriella Cotugno, Anna Morena D’Alise, Armin Lahm, Elisa Scarselli, Alfredo Nicosia, Massimo Mallardo, Emanuele Sasso & Nicola Zambrano. (2021) Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing. International Journal of Molecular Sciences 22:2, pages 477.
Crossref
Crossref
Jia-qiao Fan, Meng-Fei Wang, Hai-Long Chen, Dong Shang, Jugal K. Das & Jianxun Song. (2020) Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Molecular Cancer 19:1.
Crossref
Crossref
Xiufen Liu, Alexander Chan, Chin-Hsien Tai, Thorkell Andresson & Ira Pastan. (2020) Multiple proteases are involved in mesothelin shedding by cancer cells. Communications Biology 3:1.
Crossref
Crossref
Urs B. HagemannKatrine WickstroemStefanie HammerRoger M. BjerkeSabine Zitzmann-KolbeOlav B. RyanJenny KarlssonArne ScholzHartwig HennekesDominik MumbergAlan S. Cuthbertson. (2020) Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy. Cancer Biotherapy and Radiopharmaceuticals 35:7, pages 497-510.
Crossref
Crossref
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, Almohanad A. Alkayyal, Martina L. Jones, Stephen M. Mahler & Anwar M. Hashem. (2020) Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology 11.
Crossref
Crossref
Miriam Conte, Viviana Frantellizzi, Antonio Matto & Giuseppe De Vincentis. (2020) New insight and future perspective of mesothelin-targeted agents in nuclear medicine. Clinical and Translational Imaging 8:4, pages 265-278.
Crossref
Crossref
Ssu-Hsueh Tseng, Sung-Taek Park, Brandon Lam, Ya-Chea Tsai, Max A Cheng, Emily Farmer, Deyin Xing & Chien-Fu Hung. (2020) Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis. Journal for ImmunoTherapy of Cancer 8:1, pages e000480.
Crossref
Crossref
Jiang Lv & Peng Li. (2019) Mesothelin as a biomarker for targeted therapy. Biomarker Research 7:1.
Crossref
Crossref
Joanie Del Bano, Rémy Florès-Florès, Emmanuelle Josselin, Armelle Goubard, Laetitia Ganier, Rémy Castellano, Patrick Chames, Daniel Baty & Brigitte Kerfelec. (2019) A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. Frontiers in Immunology 10.
Crossref
Crossref
Ryan Clay & Shadab A. Siddiqi. 2019. Theranostic Approach for Pancreatic Cancer. Theranostic Approach for Pancreatic Cancer
325
367
.
Loredana Urso & Giulia Pasello. 2019. Mesothelioma. Mesothelioma
261
269
.
Alfredo Tartarone, Rosa Lerose & Michele Aieta. (2018) Is there a role for immunotherapy in malignant pleural mesothelioma?. Medical Oncology 35:7.
Crossref
Crossref
Yanyun Wang, Haibo Luo, Guanglu Che, Yanqin Li, Jun Gao, Qiongli Yang, Bin Zhou, Linbo Gao, Tao Wang, Yujie Liang & Lin Zhang. (2018) Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes. Molecular Medicine Reports.
Crossref
Crossref